HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM)’s share price rose 6.3% on Friday . The company traded as high as $2.20 and last traded at $1.93. Approximately 551,783 shares traded hands during trading, a decline of 28% from the average daily volume of 763,675 shares. The stock had previously closed at $2.06.

HTGM has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and set a $6.00 price target on shares of HTG Molecular Diagnostics in a research report on Thursday, June 29th. ValuEngine raised HTG Molecular Diagnostics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Finally, Zacks Investment Research raised HTG Molecular Diagnostics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 18th. Two analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $6.17.

The stock’s market cap is $21.52 million. The company’s 50-day moving average is $1.84 and its 200-day moving average is $1.84.

HTG Molecular Diagnostics (NASDAQ:HTGM) last posted its earnings results on Tuesday, August 8th. The medical research company reported ($0.60) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.60). The firm had revenue of $1.76 million for the quarter, compared to the consensus estimate of $1.80 million. On average, analysts expect that HTG Molecular Diagnostics, Inc. will post ($2.29) EPS for the current fiscal year.

In other news, major shareholder Holdings A/S Novo sold 1,149,813 shares of the firm’s stock in a transaction that occurred on Friday, August 25th. The shares were sold at an average price of $1.81, for a total transaction of $2,081,161.53. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders have sold 1,659,998 shares of company stock valued at $3,073,696. 7.60% of the stock is currently owned by company insiders.

Hedge funds have recently modified their holdings of the company. UBS Group AG purchased a new stake in shares of HTG Molecular Diagnostics during the 1st quarter worth approximately $137,000. Two Sigma Securities LLC purchased a new stake in shares of HTG Molecular Diagnostics during the 1st quarter worth approximately $150,000. Granahan Investment Management Inc. MA purchased a new stake in shares of HTG Molecular Diagnostics during the 1st quarter worth approximately $228,000. Finally, Vanguard Group Inc. increased its stake in shares of HTG Molecular Diagnostics by 38.9% during the 2nd quarter. Vanguard Group Inc. now owns 135,234 shares of the medical research company’s stock worth $359,000 after purchasing an additional 37,841 shares during the last quarter. Institutional investors own 21.67% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This article was originally published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.watchlistnews.com/htg-molecular-diagnostics-inc-htgm-stock-price-up-6-3/1616682.html.

About HTG Molecular Diagnostics

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Receive News & Ratings for HTG Molecular Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.